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IntRoductIon
Tuberculosis (TB) is a major global health problem. The South East Asian (SEA) Region bears an inordinately high share of the global TB burden. The SEA region accounts for nearly half (45.6%) of the global burden in terms of TB incidence. [1] Of this, India (23%) alone accounts for one-fourth of the TB burden worldwide. According to the WHO, there were an estimated 10.4 million new TB cases worldwide in 2015. India alone accounted for 2.8 million TB cases. [2] Extrapulmonary TB (EPTB) constitutes about 15%-20% of all cases of TB. [3] Out of 580,000 new cases of multidrug-resistant TB (MDR-TB) globally, 1.3 lakh MDR/Rifampicin resistance (RR) TB patients were in India. [2] The diagnosis of EPTB is challenging due to the paucibacillary nature of specimens, difficulty in obtaining specimens from deep-seated organs and inability to get an additional specimen. As a result, failure to diagnose and treat affected patients leads to increased morbidity and mortality, development of secondary resistance (including extensively drug-resistant TB) and ongoing transmission of disease. [4] Microscopy is often negative in extrapulmonary specimens; in addition, it is impossible to differentiate non-tuberculous mycobacteria (NTM) from Mycobacterium tuberculosis (MTB). Culture through the gold standard for TB diagnosis often leads to considerable delays, compromising patient care and outcome. [5] Furthermore, the lack of diagnostic infrastructure substantially aggravates the problem of EPTB diagnosis. Not only the rapid detection of TB is essential but also the early determination of MDR/RR status is a necessity.
With the increase in the number of drug-resistant TB patients around the world, appropriate diagnosis and treatment of different presentations of the disease need a special attention. [6] Hence, rapid detection of TB and early determination of MDR/RR status should be the priority.
As TB is a curable disease, the role of accurate and rapid diagnosis and treatment is vital for improving the global picture. The WHO endorsed Xpert MTB/rifampicin (RIF) assay provides a diagnosis of TB and RIF resistance (RR) within 2 h. It is not prone to cross-contamination, requires minimal biosafety facilities and minimal training. These characteristics make it potentially an attractive tool for extrapulmonary specimens. The introduction of Xpert MTB/RIF assay has helped in bridging the gap between diagnosis and treatment. [7] Studies have been conducted in EPTB samples. However, biopsy and tissue samples had not been included in Singh et al.'s study. Vadwai et al.'s study had very few cerebrospinal fluid (CSF) and body fluids samples. Although Sharma et al.'s study had a large sample size, they had not elaborated on the sample-wise sensitivity and specificity. [8] [9] [10] Therefore, this study was envisaged to evaluate the sample-wise diagnostic accuracy of Xpert MTB/RIF assay for diagnosis of EPTB and RR TB in our tertiary care setting.
mAteRIAls And methods
This was a single-centric, clinical microbiology laboratory-based prospective study conducted in the Department of Microbiology of a tertiary care setting in Mumbai, India. As per Institutional policy ethical approval was not required.
Specimens
A total of 738 consecutive EPTB samples from January 2016 to February 2017, were analysed in the study. The EPTB specimens comprised of pus (n = 132), biopsy (n = 23), tissues (n = 05), aspirates (vitreous and body lesions) (n = 06), lymph nodes (n = 70), CSF (n = 100), bronchoalveolar lavage (n = 16), pleural fluid (n = 304) and other fluids (n = 82) (peritoneal, pericardial, synovial and ascitic fluids) [ Figure 1 ]. Pus specimens included breast abscess, liver abscess, paravertebral abscess and psoas abscesses. Lymph nodes were sampled from cervical and mediastinal nodes.
Processing of samples
The samples collected by invasive procedures were processed directly. The sterile body fluids were centrifuged, and pellet was used as inoculum.
Acid-fast bacilli smears
The processed specimens were used for making smears for all the samples. Samples were stained with Ziehl-Neelsen (Z-N) method and examined with a light microscope.
Lowenstein-Jensen culture
Samples were inoculated in Lowenstein-Jensen (LJ) medium. Positive cultures were confirmed by secondary smears, culture on Para-nitrobenzoic acid, niacin and nitrate test.
Drug susceptibility testing
Drug susceptibility testing (DST) was performed for the all the positive cultures. RR was tested using economic variant of proportion method (PM) according to standard protocol. [11] Xpert MTB/RIF assay The Xpert assay was performed according to manufacturer's instructions (Cepheid, Sunnyvale, CA, USA) using the latest version of G4 cartridges. In the Xpert assay, sample reagent was added at a 2:1 ratio to clinical specimens and it was incubated for 15 min at room temperature with intermittent shaking. Following which, 2 ml of the inactivated material was transferred to the cartridge. The cartridges were inserted into the test device, and the results were generated after 90 min. [12] Repeat GeneXpert MTB/RIF tests were run for results that gave invalid, error and indeterminate results.
Bias was minimised through blinding since technicians performing conventional method, and Xpert MTB/RIF assay was unaware of the results of other tests.
Reference standard comparison
Xpert MTB/RIF assay results were compared with that of LJ culture. Furthermore, the RR detection was compared with DST on LJ medium by PM.
Statistical analysis
The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of Xpert assay were compared to TB culture on LJ medium as a reference standard using contingency two-by-two tables. P < 0.05 was considered as statistically significant. All statistical analyses were performed using MedCalc statistical software version 17.9.6. [13] 
Results
Out of total 769 samples, 31 (4.03%) samples were excluded from the study (contaminated culture -23 [ Of the 23 specimens whose cultures got contaminated, GeneXpert detected RIF sensitive MTB in 4 specimens, which would have got undetected but for Xpert assay. Of the two invalid results on GeneXpert one for pleural fluid and other for LN biopsy, repeat test on pleural fluid did not detect MTB whereas repeat test on LN biopsy could not be done, as specimen was used up for 1 st test and could not obtain 2 nd specimen. Repeat tests were performed for results that gave errors, as one was pus sample and other was pleural fluid. In both the samples, MTB was not detected. All the four NTMs, gave 'MTB not detected' result by Xpert MTB/RIF assay.
On comparison with culture, ZN smear microscopy showed sensitivity and specificity of 32.08% (95% confidence interval [CI] 19.92%-46.32%) and 94.01% (95% CI 91.97%-95.67%) respectively [ Table 2 ].
On comparison with culture, overall sensitivity, specificity, PPV and NPV of Xpert MTB/RIF assay was 84.91% (95% CI 72.41%-93.25%), 86.72% (95% CI 83.94%-89.17%), 33.09% (95% CI 28.36%-38.18%) and 98.67% (95% CI 97.51%-99.29%), respectively, the positive and negative likelihood ratio was 6.39 (95% CI 5.12-7.98) and 0.17 (95% CI 0.09-0.33), respectively. The diagnostic accuracy of Xpert MTB/RIF assay was 86.59% (95% CI 83.94%-88.86%) [ Table 3 ].
Among the diverse clinical samples, Xpert MTB/RIF assay could detect 10.57% more positivity compared to smear microscopy and 11.25% more compared to culture [ Table 1 ].
The sensitivity and specificity of Xpert MTB/RIF assay varied markedly among different clinical samples. The sensitivity was highest for lymph node and other body fluids followed by pus, CSF and pleural fluid samples. Tuberculous meningitis being a challenging diagnosis with high mortality, Xpert MTB/RIF assay offers a diagnostic advantage with a sensitivity of 71.43% (95 CI 29.04%-96.33%) [ Table 4 ].
Among culture-positive specimens, Xpert MTB/RIF assay showed a sensitivity of 94.12% (95% CI 71.31%-99.85%) in smear-positive cases and 80.56% (95% CI 63.98%-91.81%) in smear-negative cases. Although the sensitivity was low in smear-negative samples, statistically, no significant difference was seen (P = 0.41) [ Table 5 ].
Of the 53 culture-positive samples, DST was performed on all the isolates. However, 16 isolates gave invalid and 37 gave valid DST results. Of 37 isolates, RR was seen in 17 isolates (45.95%). In DST, RR was maximum in pus samples 18.92% (7/37). Xpert MTB/RIF assay detected RR in 34/136 (25%) samples, 101 were RIF sensitive and one was indeterminate. RR was highest in pus samples (13/34), followed by lymph node and pleural fluid (7/34 each). The comparison between DST results by a conventional method and RR by Xpert MTB/RIF assay was done in 34 isolates (16 isolates gave invalid DST results by conventional method and 3 samples were MTB not detected by Xpert MTB/RIF assay). Of the 34 MTB isolates, Xpert MTB/RIF assay detected Rif resistance in 9 (26.47%) isolates [ Table 6 ]. The sensitivity, specificity, PPV and NPV with 95% CI for RIF resistance detection by Xpert MTB/RIF assay was 60.00% (32.29%-83.66%), 94.74% (73.97%-99.87%), 90.00% (56.10%-98.45%) and 75.00% (61.53%-84.91%), respectively. There was no statistically significant difference between Xpert MTB/RIF assay and conventional DST method for detection of MDR TB (P = 0.31). Resistance to both RIF and isoniazid was seen in 6/37 isolates whereas 9/37 isolates were resistant to RIF and sensitive to isoniazid.
Xpert test has the advantage in providing the bacillary load in the sample. It was 'very low' in 8 samples, 'low' in 75, medium in [8, 9, 14] The sensitivity and specificity of Xpert MTB/RIF assay in our study was 84.91% and 86.72%. The observed sensitivity of Xpert MTB/RIF assay is fairly consistent with other published studies in which reported sensitivities ranged from 77.3% to 100% [ Table 7] . [4, [8] [9] [10] [14] [15] [16] [17] The heterogeneity between studies may be due to differences between patient population, diversity of clinical specimens, the quality of samples, type of EPTB, differences in sample processing and the diagnostic gold standard.
Among the culture-positive specimens, the assay showed a good sensitivity in smear-positive cases (94.12%). It showed a reasonable sensitivity in smear-negative samples as well (80.56%). This correlated well with the other published studies with sensitivity ranging from 94% to 100% for smear-positive cases [ Figure 2 ] [9, [16] [17] [18] and 63%
to 83% for smear-negative specimens. Statistically, no significant difference was seen in Xpert MTB/RIF assay sensitivity in smear positive and negative cases (P = 0.41). The Xpert MTB/RIF assay showed a very good specificity of 90.99% (95% CI 88.51%-93.09%) in culture-positive and smear-negative samples. High specificity suggests that Xpert MTB/RIF assay has a useful role as rapid rule -in test for diagnosis of EPTB in smear-negative specimens. [19] Overall, culture detected MTB in 53/738 samples (7.18%) as against Xpert MTB/RIF assay which detected MTB in 136/738 samples (18.43%). Low positivity of culture could be due to paucibacillary nature of EPTB samples and a tendency of MTB to form clumps leads to uneven distribution of bacilli. Furthermore, Xpert Assay sample reagent has better homogenisation and liquefaction efficiency. This study shows that Xpert MTB/RIF assay has a better diagnostic potential when compared to culture with a good sensitivity of 96%-100% for specimens such as lymph nodes and other fluids (i.e., ascitic, pericardial, synovial and peritoneal fluids) and pus when compared with other published studies. [8] [9] [10] 14, [20] [21] [22] In our study, low sensitivity was seen with pleural fluids. In this study, CSF showed a moderate sensitivity of 71.43% (95% CI 29%-96.33%) that was similar to other studies. Our study showed a higher sensitivity for CSF samples as compared with a study by Vadwai et al. which showed a lower sensitivity of 29% [ Figure 3 ].
In this study, the sensitivity and specificity for RR detection by Xpert MTB/RIF assay was 60% (95% CI 32.29%-83.66%) and specificity of 94.74% (95% CI 33.2%-89.65%) when compared to DST by conventional method. The sensitivity was low when compared to other studies. [8] [9] [10] which could be due to lower sample size (34) in our study. Statistically, no significant difference was seen in RR detection by Xpert MTB/RIF assay and DST (P = 0.31).
Six false-negative RR was detected by Xpert MTB/RIF assay in the present study. These discordant results might be due to mutation outside the RR determining the region, which needs to be solved by sequencing of rpoB gene. One false-positive result was given by the assay. This discrepancy could be due to mixed TB infections. Mixed MTB infections have been suggested to be responsible for false negative and positive results for RIF by Xpert. [23] Heteroresistance defined as the presence of both sensitive and resistant MTB populations is often suggested to be responsible for discordant DST results. [24] One limitation of the present study was that the culture was done on solid medium. The pre-processing of specimens with NALC NaOH method was not done, which could have resulted in less contamination in culture. Another limitation of the study was that since this was primarily a laboratory-based study, the clinical and radiological findings could not be obtained. The composite gold standard (treatment, radiology and clinical response) would have improved the specificity of the study. However, despite the limitations, the results of the study remain significant since it shows the promising diagnostic potential of the test.
conclusIon
Overall, the Xpert MTB/RIF assay has a considerably good sensitivity and specificity. Its performance varies with the clinical specimens. It is a valuable diagnostic tool for smear-negative EPTB cases. Undoubtedly, with its short turnaround time along with detection of both MTB and MDR status, Xpert MTB/RIF assay perfectly fits the requirements of Indian health-care settings.
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